Loading...
Loading...
ViroPharma Incorporated
VPHM today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business during the 30th Annual J.P. Morgan Healthcare Conference.
For the year 2012, ViroPharma expects the following:
Worldwide net product sales are expected to be $600 to $660 million
Net U.S. Cinryze sales are expected to be $310 to $330 million.
Net Vancocin sales are expected to be $260 to $310 million; and
Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in